Xingshulin Files IPO Prospectus: Revolutionizing Innovative Drug Marketing in the GPT Era with Integrated Physician-Patient Digital Solutions

May 25 marked the conclusion of the 5th Digital Healthcare and Marketing Innovation Summit. As a premier industry event, the summit brought together numerous leading experts to jointly explore digital transformation and marketing innovations in the pharmaceutical sector.

Dr. Zhang Yusheng, Founder and CEO of Xingshulin, was also invited to attend the conference. As one of the representative entrepreneurs, he delivered a keynote speech titled “GPT-Empowered Integrated Doctor-Patient Innovative Drug Marketing Practices” on the 24th, showcasing to the outside world how Xingshulin empowers innovative pharmaceutical companies through more efficient and cost-effective integrated doctor-patient digital marketing solutions in the AIGC era.

Contrary to our previous impressions, Xingshulin, founded in 2011, has long ceased to be merely a platform providing tools for physicians after more than a decade of development. The company’s gold award-winning “Innovative Integrated Doctor-Patient Service” further underscores this transformation: digital marketing for innovative drugs through integrated doctor-patient services has become the core business of this enterprise, which has accumulated decades of doctor-patient resources, and has achieved highly successful practical implementation.

China’s pharmaceutical market is ushering in a new wave of digital transformation. Digital marketing in the pharmaceutical sector has drawn significant attention due to its substantial market size. In particular, digital marketing for innovative drugs is regarded as the most promising growth track. On one hand, China’s innovative drug market continues to expand rapidly, with numerous innovative enterprises entering the field. On the other hand, factors such as the impact of national medical insurance and volume-based procurement policies, along with intense competition around innovative therapeutic targets, have placed pressure on innovative drug manufacturers to reduce costs and improve efficiency, creating various challenges that necessitate third-party support for their commercialization efforts. This situation, in turn, presents development opportunities for third-party companies specializing in providing marketing services to innovative drug manufacturers.

Xingshulin seized this opportunity, which was also facilitated by the doctor-patient resources and service capabilities it had accumulated over decades of development.

First, Xingshulin’s profound accumulation in medical resources.This is attributable to Xingshulin’s continuous expansion into clinical scenarios involving medical practice, education, and research for healthcare professionals, as well as patient-focused scenarios encompassing screening, triage, follow-up visits, rehabilitation, and long-term follow-up.

Dr. Zhang Yusheng, Founder and CEO of Xingshulin, is a graduate of Peking Union Medical College (PUMC) and previously served as Research Manager in the Medical Strategy Department at Wellpoint, the largest health insurance group in the United States. Deeply aware of the needs and pain points associated with enhancing physicians’ professional competencies, Dr. Zhang founded Xingshulin in 2011 with the initial vision of digitizing the “Three Treasures of PUMC”—the library, the medical records department, and the mentorship of senior professors—which are highly effective in boosting clinicians’ professional capabilities. By developing digital platforms and tools such as YiKoudai (MedPocket), BingliJia (Medical Record Clip), and Cloud Academy, Xingshulin leverages digital solutions to meet physicians’ clinical needs in medical practice, education, and research. To date, Xingshulin has gradually established a healthcare collaboration network, with nearly 2 million registered physicians on its platform.

Furthermore, by launching the “Cloud Ward” feature within its “Medical Record Folder” for patient follow-up management and introducing the Xingshulin Internet Hospital to provide services such as follow-up consultations, Xingshulin has currently reached more than 400,000 patients and their families. This number continues to grow steadily as the trend toward online doctor-patient interactions accelerates.

Second, the continuous accumulation of massive real-world data.In the course of serving physicians and patients, the Xingshulin platform has continuously accumulated a vast volume of real-world clinical case data, with data granularity reaching research-grade standards. This has positioned Xingshulin as a platform that truly understands both physicians and patients.

Third, the continuous accumulation of experience in serving pharmaceutical companies.As early as 2015, Xingshulin began collaborating with pharmaceutical companies, leveraging its accumulated capabilities to provide innovative marketing solutions that help these companies better reach physicians and patients. Over the past few years, Xingshulin has served a cumulative total of 165 pharmaceutical companies, including many well-known multinational corporations and leading domestic firms. The company has also undertaken nearly 700 projects in total.

Fourth, sustained investment in research and development.Over the years, Xingshulin has consistently maintained a high level of R&D investment. Its Doctor Workbench, designed to support physicians in clinical practice, teaching, and research; its Intelligent Follow-up System for patient consultations and follow-up management; its Digital Marketing Cloud Platform facilitating the commercialization of innovative medical products; its software platform providing technical service support; and the numerous systems delivering technical implementation for various business services have all reached maturity and perfection.

Among these, Xingshulin’s marketing cloud platform—featuring one-stop, online-configurable PaaS solutions such as Apricot Reach, Apricot Uptake, Apricot Care, Apricot Coordinate, and Apricot Evidence—has already covered multiple scenarios in pharmaceutical companies’ digital marketing.

Currently,Xingshulin is one of the few companies in the field of AIGC for digital healthcare that fully possesses scenario-specific applications, vertical-domain data, and algorithmic technologies, while having successfully validated business scenarios and deployed commercial products.

For innovative pharmaceutical companies, there are two core issues to address: first, how to achieve rapid sales growth after the launch of new drugs; and second, how to embed product value propositions in the minds of doctors and patients to continuously gain clinical treatment benefits.

Ultimately, it all comes down to how to more effectively influence physicians and patients.

From the physician’s perspective, facilitating clinical decision-making requires more than merely disseminating knowledge about innovative drugs; it necessitates leveraging real-world clinical scenarios to foster physicians’ recognition of product value. From the patient’s perspective, maximizing therapeutic benefits entails helping patients understand treatment gains and employing diverse strategies to enhance medication safety and accessibility.

However, third-party pharmaceutical marketing services have often failed to effectively serve all stakeholders. In contrast, Xingshulin’s GPT-powered integrated digital marketing management platform for physicians and patients truly delivers value to both parties while simultaneously driving the market adoption and volume growth of innovative drugs—

①In Physician Education, when patients are enrolled in the project, Xingshulin, leveraging GPT-based semantic analysis, can assist physicians in precisely designing core metrics, achieving data visualization, and effectively analyzing patient data.and automatically provide feedback on assessment results based on GPT capabilities, helping physicians accurately appreciate the differentiated clinical value of innovative drug products and change their perceptions.When physicians recognize its value and engage in academic sharing, its proprietary AI case-generation system enables them to create presentation slides with a single click. By shifting and influencing the perspectives of key opinion leaders, it drives changes in clinical prescribing decisions.

②In terms of patient management，Xingshulin leverages GPT technology to better drive patient management, transforming the previous landscape where patient management outcomes were difficult to measure and complex diseases were challenging to manage, while significantly enhancing management efficiency.Currently, Xingshulin adopts a “three-specialist co-management” mechanism, providing patients with long-term management services through teams of health managers, specialist physicians, and collaborative consulting experts. During service delivery, its proprietary GPT model—trained on Xingshulin’s own disease knowledge base and historical de-identified data—can already assist health managers in collecting data to assess patients’ current conditions and provide specialist physicians with auxiliary diagnostic and treatment recommendations, significantly reducing the previous reliance on manual labor. Ultimately, this has led to an extension of patients’ Duration of Therapy (DOT).

Unlike other companies currently offering digital marketing solutions for the pharmaceutical industry, Xingshulin’s solution features several distinctive characteristics:

First, empower offline academic representatives.Post-pandemic, offline pharmaceutical marketing has returned to the forefront. Xingshulin’s integrated digital marketing solution for physicians and patients empowers field medical representatives by leveraging GPT capabilities to collect patient case data, enabling case-based physician visits through Case Call. This fundamentally transforms the previously inefficient representative visit model.

Secondly, it enables the return on investment (ROI) to be measurable.. In the past, innovative pharmaceutical companies often struggled to measure ROI due to their extensive marketing campaigns. However, there is a clear correlation between physicians' drug awareness and their clinical decision-making when prescribing medications. By developing corresponding models, Xingshulin helps pharmaceutical companies achieve precise ROI calculations, making it easier for innovative drug enterprises to see the effectiveness of their marketing efforts.

Finally, it is about value empowerment based on GPT.It is foreseeable that as Xingshulin accumulates more consultation response data in its disease-related databases, the accuracy and sensitivity of GPT will be further enhanced.Ultimately, by integrating GPT capabilities, Xingshulin will further enhance the effectiveness of its holistic doctor-patient integrated digital marketing solutions while reducing marketing costs.

It is also based on the recognition of Xingshulin's GPT-empowered integrated digital marketing solution for doctors and patients,Currently, dozens of new drugs have partnered with Xingshulin.For example, a certain oncology drug in the field of breast cancer, with the help of Xingshulin's digital marketing solutions, achieved coverage of 500+ oncologists and 5,000+ cancer patients. Through forms such as physician education and patient care, the post-diagnosis care project for breast cancer patients created by Xingshulin has realized an improvement in medication benefits for patients and an effective extension of DOT (Duration of Treatment).

“Our partnership with Xingshulin has given our product a distinct advantage in market promotion. For pharmaceutical companies, digital marketing has become an indispensable part of the industry, and Xingshulin’s integrated doctor-patient digital marketing solution provides comprehensive, intelligent, and efficient digital marketing services.” This statement was made by one pharmaceutical company. Based on these tangible results, the number of potential prospective clients for Xingshulin continues to grow.

The era of extensive pharmaceutical marketing has passed. In the current landscape, which places greater emphasis on marketing return on investment (ROI) and precision marketing, innovative drug companies undoubtedly seek to maximize marketing returns at more controllable costs.

By continuously accumulating medical resources and precise medical data, integrating GPT capabilities, reducing costs, and improving efficiency, Xingshulin has created an integrated digital marketing solution for doctors and patients, and is now seizing a prime opportunity for rapid market expansion.

The market will undoubtedly reward every practitioner willing to delve deeply into niche segments. The field of digital pharmaceutical marketing is no exception.